

Dermatological Conditions

Reference Number: F4815
Date of Response: 09/09/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Royal Devon's Eastern FOI Office Response

Q1. How many patients were treated in last 4 months by the Dermatology department (for any disease) with each of the following:

- Abrocitinib – **0 Patients**
- Acitretin – **108 Patients**
- Alitretinoin – **11 Patients**
- Azathioprine – **0 Patients**
- Baricitinib – *** Patients**
- Ciclosporin – **25 Patients**
- Dupilumab – **108 Patients**
- Methotrexate – **157 Patients**
- Mycophenolate mofetil – **8 Patients**
- Pimecrolimus – **5 Patients**
- Tacrolimus ointment – **48 Patients**
- Tralokinumab – **0 Patients**
- Upadacitinib – *** Patients**

* - **Low number suppressed to protect patient identity. ≤5.**

In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.

Q2. Of the patients treated in the last 4 months with any of the products listed in Q1, how many patients were paediatric (age 17 or under)? – **43 Patients**

Q3. How many patients were treated in the last 4 months with phototherapy (UVB or PUVA) for atopic dermatitis ONLY? – **0 Patients**